Effect of beta-lactamase inhibitors on beta-lactamases from anaerobic bacteria
- PMID: 1338315
- DOI: 10.1007/BF01967805
Effect of beta-lactamase inhibitors on beta-lactamases from anaerobic bacteria
Abstract
Three beta-lactamase inhibitors in clinical use--clavulanic acid, sulbactam and tazobactam--were investigated for their activity on beta-lactamases from Bacteroides uniformis, Clostridium butyricum and Fusobacterium nucleatum. Purification of the beta-lactamases was carried out by anion-exchange chromatography, gel filtration and FPLC. The inactivation of beta-lactamase activity was determined spectrophotometrically with nitrocefin as substrate. Various concentrations of the inhibitors were preincubated at 30 degrees C together with the enzyme for different periods of time before determination of the beta-lactamase activity. The three beta-lactamases tested were more susceptible to tazobactam than to clavulanic acid and sulbactam. Clavulanic acid and sulbactam reduced the enzyme activity of the Bacteroides uniformis beta-lactamase more effectively than the Clostridium butyricum and Fusobacterium nucleatum beta-lactamases.
Similar articles
-
Effect of clavulanic acid, sulbactam and tazobactam on three different beta-lactamases from Bacteroides uniformis, Clostridium butyricum and Fusobacterium nucleatum.J Antimicrob Chemother. 1992 Jul;30(1):17-25. doi: 10.1093/jac/30.1.17. J Antimicrob Chemother. 1992. PMID: 1331018
-
Comparative activity of beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with beta-lactams against beta-lactamase-producing anaerobes.Antimicrob Agents Chemother. 1986 Nov;30(5):789-91. doi: 10.1128/AAC.30.5.789. Antimicrob Agents Chemother. 1986. PMID: 3026241 Free PMC article.
-
Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.Antimicrob Agents Chemother. 1989 Nov;33(11):1964-9. doi: 10.1128/AAC.33.11.1964. Antimicrob Agents Chemother. 1989. PMID: 2558615 Free PMC article.
-
Evolution of beta-lactamase inhibitors.Rev Infect Dis. 1991 Jul-Aug;13 Suppl 9:S727-32. doi: 10.1093/clinids/13.supplement_9.s727. Rev Infect Dis. 1991. PMID: 1656513 Review.
-
Beta-lactam/beta-lactamase inhibitor combinations: development, antibacterial activity and clinical applications.Infection. 1995 Jul-Aug;23(4):191-200. doi: 10.1007/BF01781195. Infection. 1995. PMID: 8522374 Review. No abstract available.
Cited by
-
Clinical role of beta-lactam/beta-lactamase inhibitor combinations.Drugs. 2003;63(14):1511-24. doi: 10.2165/00003495-200363140-00006. Drugs. 2003. PMID: 12834367 Review.
-
Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.Drugs. 1994 Mar;47(3):506-35. doi: 10.2165/00003495-199447030-00008. Drugs. 1994. PMID: 7514977 Review.